BREAKING ADVANCES

6377  Highlights from Recent Cancer Literature

REVIEWS

6379  Decoding the Histone Code: Role of H3K36me3 in Mismatch Repair and Implications for Cancer Susceptibility and Therapy
Guo-Min Li

6384  Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?
Klaus Pantel and Catherine Aix-Panabieres

MEETING REPORT

6389  The Hippo Tumor Suppressor Network: From Organ Size Control to Stem Cells and Cancer
Georg Halder and Fernando D. Camargo

PRIORITY REPORT

6393  Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem-like Cells to Protect Them from Chemotherapy
Matilde Todaro, Alice Turdo, Monica Bartucci, Flora Jovino, Rosanna Dattilo, Marco Biffoni, Giorgio Stassi, Giulia Federici, Ruggero De Maria, and Ann Zeuner
Précis: A growth factor that has been used in the oncology clinic to support red blood cell counts in patients receiving chemotherapy is found to counter the therapeutic killing of cancer stem-like cells, offering a mechanistic explanation for why cancer patients receiving this growth factor have shown reduced survival.

INTEGRATED SYSTEMS AND TECHNOLOGIES

6401  A Transcriptional and Metabolic Signature of Primary Aneuploidy Is Present in Chromosomally Unstable Cancer Cells and Informs Clinical Prognosis
Jason M. Sheltzer
Précis: Chromosomal instability in cancer cells is associated with a transcriptional stress response that has prognostic significance in various types of human malignant.

MICROENVIRONMENT AND IMMUNOLOGY

6413  GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-α
Gary Kohanbash, Kayla McKaveney, Massashi Sakaki, Ryo Ueda, Arlan H. Mintz, Nduka Amankulor, Mitsuaki Fujita, John R. O'Hlst, and Hideho Okada
Précis: These findings reveal the operation of immunosuppressive mechanisms in the glioblastoma microenvironment driven by GM-CSF, a factor used in the clinic to elevate white blood cell counts in patients, suggesting clinical risks arising from its use.

6424  Substance P Autocrine Signaling Contributes to Persistent HER2 Activation That Drives Malignant Progression and Drug Resistance in Breast Cancer
Susana Garcia-Recio, Gemma Fuster, Patricia Fernandez-Nogueira, Eva M. Pastor-Marroyo, So Yeon Park, Cristina Mayordomo, Elisabet Ametller, Mario Mancino, Xavier Gonzalez-Farre, Hege G. Russnes, Pablo Engel, Domiziana Costamagna, Pedro L. Fernandez, Pedro Gascon, and Vanessa Almendro
Précis: This work illuminates the oncogenic cooperation between HER2 and a substance P receptor involved in pain signaling, providing a novel link between cancer inflammation and progression that might be targeted by substance P antagonists being explored in the clinic.

MOLECULAR AND CELLULAR PATHOBIOLOGY

6435  miR-153 Supports Colorectal Cancer Progression via Pleiotropic Effects That Enhance Invasion and Chemotherapeutic Resistance
Lei Zhang, Karen Pickard, Veronika Jenei, Marc D. Bullock, Amanda Bruce, Richard Mitter, Gavin Kelly, Christos Paraskeva, John Stellford, John Primrose, Gareth J. Thomas, Graham Packham, and Alex H. Mirnezami
Précis: MicroRNAs that facilitate progression and mediate drug resistance in advanced cancers have increased appeal as treatment targets, given the more frequent lack of effective therapies at late stages of disease.
**THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY**

**6462**  
Photodynamic Therapy of Murine Mastocytoma Induces Specific Immune Responses against the Cancer/Testis Antigen P1A  
Pawel Mroz, Fatma Vatansever, Angelika Muchowicz, and Michael R. Hamblin  
*Précis:* Effective photodynamic therapy used to treat certain cancers may act as antigen-specific immunotherapy.

**6471**  
Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization  
Bohua Li, Yanchun Meng, Lei Zheng, Xumin Zhang, Qing Tong, Wenlong Tan, Shi Hu, Hui Li, Yang Chen, Jinning Song, Ge Zhang, Lei Zhao, Dapeng Zhang, Sheng Hou, Weizhu Qian, and Yajun Guo  
*Précis:* Using a bispecific antibody to block ErbB2/HER2 heterodimerization on the surface of breast cancer cells may provide a strategy to overcome resistance to Herceptin that remains a major clinical challenge in breast cancer patients.

**6484**  
A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance  
*Précis:* These findings address deficiencies in existing drugs that block ribonucleotide reductase, offering preclinical validation of a promising new class of inhibitors against this valid target that could find broad use to treat many human cancers.

**TUMOR AND STEM CELL BIOLOGY**

**6504**  
MYC Phosphorylation at Novel Regulatory Regions Suppresses Transforming Activity  
Amanda R. Wasylishen, Michelle Chen-Seng-Yue, Christina Rros, Dharmendra Dingar, William B. Tu, Manpreet Kalkat, Pak-Kei Chan, Peter J. Mullen, Ling Huang, Natalie Meyer, Brian Raught, Paul C. Boutros, and Linda Z. Penn  
*Précis:* MYC phosphorylation mutants with super-transforming activity that were identified in this study point the way toward new therapeutic targets to attack MYC by a backdoor approach.

**6516**  
TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase  
Xiaoping Wang, Hitomi Saso, Takayuki Iwamoto, Weiya Xia, Yun Gong, Lajos Pusztai, Wendy A. Woodward, James M. Reuben, Steven L. Warner, David J. Beaus, Gabriel N. Hortobagyi, Mien-Chie Hung, and Naoto T. Ueno  
*Précis:* These findings provide key new insights into the molecular pathobiology of the most aggressive form of breast cancer, rationalizing the Axl receptor signaling pathway as a therapeutic target for treatment of this lethal disease.

**6526**  
Nitric Oxide Production Upregulates Wnt/β-Catenin Signaling by Inhibiting Dickkopf-1  
Qiang Du, Xinglu Zhang, Quan Liu, Xianghong Zhang, Christian E. Bartels, and David A. Geller  
*Précis:* In addressing the complex role of nitric oxide in cancer, this study furthers evidence of an oncogenic contribution that is mediated by a mechanism that stimulates Wnt/β-catenin signaling, a central pathway for carcinogenesis.

**CORRECTION**

6538  
Correction: Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression
ABOUT THE COVER

miR-153 leads to increased invasiveness in colorectal cancer. Using mouse tumor xenografts, it was found that colorectal tumors with inhibition of miR-153 show a clean edge of tumor spheroid and fewer invasive fronts into the surrounding stroma (magnification, ×400) in contrast to controls with a more locally invasive tumor phenotype. For details, see article by Zhang and colleagues on page 6435.